Please login to the form below

Not currently logged in
Email:
Password:

Dr Ian Smith appointed CEO of Glide Pharma

Founder of Meridica and former Glaxo and Pfizer research executive will lead UK speciality pharma company

Dr Ian Smith - Glide Pharma, CEOUK speciality pharma firm Glide Pharma has appointed a new CEO, picking Dr Ian Smith, the former founder of the Pfizer-acquired drug delivery company Meridica.

Dr Smith, who also served as head of inhalation and device product development groups at both Glaxo and Pfizer, will take over from James Otter who had served as Glide's CEO since September, 2010 and remain as a member of the board of directors.

The company focuses on the development of solid dose formulations of therapeutics and vaccines to be used with its needle-free solid dose injector technology.

Gaining his PhD in 1972, Smith has spent the past 30 years in the pharma industry, with his most recent role as founder and director of industry consultancy firm H12 Consulting.

From November 2004 to April 2010, he was head of inhalation and devices centre of emphasis at Pfizer R&D, with global responsibility for inhaled product developments.

He held a similar role at Glaxo from November 1983 until July 1995, serving as head of inhalation product development and pharmaceutical technology.

In 2001, Dr Smith also set up and served as CEO of drug delivery firm Meridica. The company, which focused on inhaler device development, was acquired by Pfizer in 2004, with a valuation of $140m.

Commenting on his appointment, Dr Smith said: “Having spent many years in the industry, I have keenly observed the progress of Glide's unique solid dose needle-free technology, and I now look forward to playing a key role in accelerating its advance towards commercialisation.”

11th January 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics